Dostarlimab was used in rectal cancer at Sloan Kettering
Resuls were amazing just look at the pics in the June NEJM
The cancers disappear,
And when combined with efti results could eclipse efti/Keytruda results.
But Tacti 002 trial indicate efti/Keytruda combo will beat Dostarlimab.
Looks like efti is the key to the next Immuno King
Maybe GSK is making an offer knowing this
Dostarlimab was used in rectal cancer at Sloan Kettering Resuls...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $584.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 42.0¢ | 40.0¢ | $833.9K | 2.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 38358 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 105000 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
41.5¢ |
Change
0.000 ( 3.29 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 42.0¢ | 40.5¢ | 804683 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| IMM (ASX) Chart |